News
Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance(1 ...
Vepdegestrant extended PFS vs fulvestrant in patients with ESR1m+, ER+/HER2– breast cancer who progressed on CDK 4/6 inhibitors and endocrine therapy. The investigational oral PROTAC ER degrader ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback